Semaglutide reduces risk of kidney decline or death in type 2 diabetes and CKD

This randomized controlled trial evaluated the efficacy of once-weekly subcutaneous semaglutide 1.0 mg in participants with type 2 diabetes and chronic kidney disease. The study population included 3,533 individuals. The primary outcome was defined as a composite of at least 50% estimated glomerular filtration rate decline, eGFR less than 15 mL/min/1.73 m, dialysis, transplantation, or kidney or cardiovascular death. The comparator was placebo. The follow-up period was 120.0 months. Results were analyzed across multiple subgroups based on cardiovascular history and risk profiles. Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported in the provided evidence. Limitations regarding study design, setting, or potential biases were not reported. Funding sources and conflicts of interest were not reported.

The primary kidney outcome results demonstrated a reduction in risk across all examined subgroups. For participants with atherosclerotic cardiovascular disease, the hazard ratio was 0.80 with a 95% confidence interval of 0.63 to 1.02. The absolute numbers for this subgroup were 119 of 593 versus 146 of 605. The p-value for interaction was 0.62. For participants without atherosclerotic cardiovascular disease, the hazard ratio was 0.74 with a 95% confidence interval of 0.62 to 0.89. The absolute numbers were 212 of 1,174 versus 264 of 1,161. The p-value for interaction was 0.40. For participants with heart failure, the hazard ratio was 0.67 with a 95% confidence interval of 0.49 to 0.93. The absolute numbers were 67 of 342 versus 88 of 336. The p-value for interaction was 0.40. For participants without heart failure, the hazard ratio was 0.79 with a 95% confidence interval of 0.67 to 0.93. The absolute numbers were 264 of 1,424 versus 322 of 1,430. The p-value for interaction was 0.99. For participants with high total cardiovascular disease risk, the hazard ratio was 0.73 with a 95% confidence interval of 0.58 to 0.91. The absolute numbers were 134 of 675 versus 168 of 654. The p-value for interaction was 0.99. For participants without high total cardiovascular disease risk, the hazard ratio was 0.73 with a 95% confidence interval of 0.49 to 1.08. The absolute numbers were 44 of 331 versus 58 of 340.

Secondary outcomes focused on all-cause death. For participants with atherosclerotic cardiovascular disease, the hazard ratio was 0.82 with a 95% confidence interval of 0.63 to 1.07. The absolute numbers were 99 of 593 versus 121 of 605. The p-value for interaction was 0.79. For participants without atherosclerotic cardiovascular disease, the hazard ratio was 0.78 with a 95% confidence interval of 0.62 to 0.99. The absolute numbers were 128 of 1,174 versus 158 of 1,161. The p-value for interaction was 0.74. For participants with heart failure, the hazard ratio was 0.75 with a 95% confidence interval of 0.54 to 1.05. The absolute numbers were 64 of 342 versus 79 of 336. The p-value for interaction was 0.74. For participants without heart failure, the hazard ratio was 0.81 with a 95% confidence interval of 0.66 to 0.99. The absolute numbers were 163 of 1,424 versus 200 of 1,430. The p-value for interaction was 0.63. For participants with high total cardiovascular disease risk, the hazard ratio was 0.71 with a 95% confidence interval of 0.52 to 0.95. The absolute numbers were 73 of 675 versus 98 of 654. The p-value for interaction was 0.63. For participants without high total cardiovascular disease risk, the hazard ratio was 0.82 with a 95% confidence interval of 0.47 to 1.43. The absolute numbers were 23 of 331 versus 28 of 340.

Comparison to prior landmark studies in this therapeutic area is not provided in the evidence. The study design, setting, and population details beyond the sample size and conditions are not reported. Methodological limitations and potential biases were not reported. The evidence does not allow for a definitive comparison with previous trials. Questions remain unanswered regarding long-term safety profiles beyond the reported follow-up and the specific mechanisms driving the observed renal benefits. The absence of reported safety data limits the ability to fully assess tolerability in this specific population. Clinicians should interpret these findings with caution given the lack of reported adverse event rates and the specific subgroup analyses which may not apply to all patients. The study provides data on risk reduction but does not establish a complete safety profile. Further research is needed to address the gaps in safety reporting and to confirm these findings in broader populations. The results indicate a potential benefit for patients with type 2 diabetes and CKD but require integration with existing clinical knowledge and patient-specific factors.